1. Home
  2. GPRO vs BDTX Comparison

GPRO vs BDTX Comparison

Compare GPRO & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoPro Inc.

GPRO

GoPro Inc.

HOLD

Current Price

$0.78

Market Cap

154.6M

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.82

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRO
BDTX
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.6M
171.9M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
GPRO
BDTX
Price
$0.78
$1.82
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$9.67
AVG Volume (30 Days)
6.9M
2.0M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
79.08
130.71
EPS
N/A
N/A
Revenue
$651,542,000.00
N/A
Revenue This Year
$23.14
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$1.82
52 Week High
$3.05
$4.94

Technical Indicators

Market Signals
Indicator
GPRO
BDTX
Relative Strength Index (RSI) 32.19 33.35
Support Level $0.74 N/A
Resistance Level $1.88 $2.30
Average True Range (ATR) 0.10 0.18
MACD -0.04 -0.06
Stochastic Oscillator 2.36 1.93

Price Performance

Historical Comparison
GPRO
BDTX

About GPRO GoPro Inc.

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: